Compare CLDT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLDT | DCTH |
|---|---|---|
| Founded | 2009 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.3M | 578.4M |
| IPO Year | 2009 | 2015 |
| Metric | CLDT | DCTH |
|---|---|---|
| Price | $16.14 | $20.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $16.17 | ★ $28.60 |
| AVG Volume (30 Days) | 565.4K | ★ 653.4K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ 275.00 | 107.53 |
| EPS | 0.11 | ★ 0.21 |
| Revenue | ★ $295,075,000.00 | N/A |
| Revenue This Year | $9.69 | $36.66 |
| Revenue Next Year | $3.41 | $20.12 |
| P/E Ratio | $147.18 | ★ $101.90 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.38 | $8.12 |
| 52 Week High | $16.61 | $22.51 |
| Indicator | CLDT | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 75.29 | 72.77 |
| Support Level | $12.36 | $10.76 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.49 | 1.10 |
| MACD | 0.11 | 0.81 |
| Stochastic Oscillator | 81.42 | 79.30 |
Chatham Lodging Trust is a U.S.-based real estate investment trust that invests in upscale extended-stay hotels. The firm operates across various states in the U.S., including California, New York, Texas, Florida, Minnesota, Massachusetts, and Pennsylvania, among others. Substantially all of the company's assets are held and operated by its operating partnership, Chatham Lodging, LP. Chatham Lodging LP and its subsidiaries lease the overall company's hotels. Chatham's revenue streams include room, food and beverage, and other. The room comprises the majority of its total revenue. Chatham's hotels operate under various brands, which include Hilton, Marriott, and Hyatt.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.